Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKEYSX)

Drug Name

MDL 101,731 Drug Info

Synonyms

Tezacitabine; Fmdc cpd; 130306-02-4; Mdl 101,731; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331

Indication

Disease Entry	ICD 11	Status	REF
Gastric adenocarcinoma	2B72	Discontinued in Phase 2	[1]

Cross-matching ID

PubChem CID: 6435808
CAS Number: CAS 130306-02-4
TTD Drug ID: DMKEYSX

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Ribonucleoside-diphosphate reductase M2 (RRM2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[3]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[3]
CO-101	DMH5GQU	Pancreatic cancer	2C10	Phase 2	[4]
Triapine	DM7XZY5	Nerve injury	ND56.4	Phase 2	[5]
CALAA-01	DMT4Z5B	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
LY-2334737	DMCBV20	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
Gallium maltolate	DMX0Z51	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[8]
NKP-46	DMK8UD0	Solid tumour/cancer	2A00-2F9Z	Preclinical	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ribonucleoside-diphosphate reductase M2 (RRM2)	TTBWDI0	RIR2_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002544)
2	Tezacitabine Hoechst Marion Roussel.Curr Opin Investig Drugs.2000 Sep;1(1):135-40.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	Cellular pharmacology of gemcitabine. Ann Oncol. 2006 May;17 Suppl 5:v7-12.
5	PAN-811 inhibits oxidative stress-induced cell death of human Alzheimer's disease-derived and age-matched olfactory neuroepithelial cells via suppression of intracellular reactive oxygen species. J Alzheimers Dis. 2009;17(3):611-9.
6	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
7	Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Jun;71(6):1645-55.
8	Gallium maltolate is a promising chemotherapeutic agent for the treatment of hepatocellular carcinoma. Anticancer Res. 2006 May-Jun;26(3A):1739-43.
9	Phase I and pharmacokinetic study of the oral tris-(8-quinolinolato)gallium(III) complex (FFC11, KP46) in patients with solid tumors - a study of the CESAR Central European Society for Anticancer Drug Research - EWIV. J Clin Oncol (Meeting Abstracts) June 2005 vol. 23 no. 16_suppl 3205.